Loading people...
Dani Bach primarily invests in early-stage technology companies within the artificial intelligence (AI), enterprise Software-as-a-Service (SaaS), and deep tech sectors. She seeks out disruptive innovations with strong market potential.
Dani Bach works as a Partner at NanoDimension, a prominent venture capital firm that invests in groundbreaking technology companies.
Dani Bach is a distinguished Partner at NanoDimension, a leading venture capital firm known for its forward-thinking investments in the technology sector. As a pivotal member of the investment team, Dani plays a crucial role in shaping NanoDimension's strategy, identifying promising early-stage companies, and providing invaluable guidance to portfolio founders. Her expertise lies in recognizing disruptive potential and fostering the growth of innovative startups from their foundational stages.
At NanoDimension, Dani's investment focus areas are sharply defined, primarily encompassing artificial intelligence, enterprise Software-as-a-Service (SaaS), and deep tech. Within AI, she is particularly interested in applications that leverage machine learning, natural language processing, and computer vision to solve complex real-world problems. Her SaaS investments often target solutions that enhance productivity, streamline operations, or create new market efficiencies for businesses across various industries. In deep tech, Dani seeks out foundational technologies with long-term transformative power, including advanced computing paradigms and novel scientific breakthroughs that have scalable commercial applications. She is known for her rigorous due diligence and her ability to discern truly groundbreaking innovations from fleeting trends.
Dani's career trajectory is marked by a deep understanding of technology and a passion for entrepreneurship. Prior to joining NanoDimension, she honed her skills in both operational and strategic roles within the tech industry. After earning her degree in Computer Science, Dani spent several years as a product lead at a fast-growing enterprise software company, where she was instrumental in launching several successful products. This hands-on experience provided her with a unique perspective on product development, market fit, and scaling challenges, which she now applies to her investment decisions. Her transition into venture capital was driven by a desire to empower a broader range of innovators and contribute to the ecosystem at a higher level.
Throughout her tenure at NanoDimension, Dani Bach has been instrumental in the success of numerous portfolio companies. While specific investment details remain confidential, her contributions have consistently led to significant growth and strategic exits for the firms she has backed. She is celebrated for her ability to forge strong, collaborative relationships with founders, offering not just capital but also strategic insights, operational advice, and access to NanoDimension's extensive network. Her commitment extends beyond financial investment, actively working with teams to navigate market challenges, refine business models, and achieve their full potential.
Dani's vision for the future of technology is clear: to support companies that are not just building products, but shaping industries and solving humanity's most pressing challenges. Her work at NanoDimension continues to solidify the firm's reputation as a leader in identifying and nurturing the next generation of technological pioneers. For founders seeking a partner who combines deep technical acumen with strategic business insight, Dani Bach represents an invaluable resource in the competitive landscape of venture capital.
Dani Bach is a Partner at NanoDimension based in London, England, where he focuses on early-stage life sciences and biotechnology venture capital investments. Before joining the investment firm in 2020, he served as Managing Partner at Aravis and Director of Life Sciences at Imperial Innovations. He also spent several years working as a venture investor at Index Ventures, guiding therapeutics and health-tech startups through clinical development and eventual exits. His academic foundation includes a PhD in Molecular Biology from the University of Barcelona and postdoctoral research at the University of Geneva. Throughout his career, he has held board seats at numerous European and American biotech companies, including Levicept and Coley Pharmaceutical Group. Bach currently leverages his extensive scientific expertise to identify, fund, and scale emerging therapeutics and digital health enterprises across the broader global market.
